期刊文献+

生物等效性评价及相关问题 被引量:4

Bioequivalence studies and related problems
下载PDF
导出
摘要 生物等效性在新药研究、非专利药开发和药品上市后评价中具有重要作用。本文从实验方法学、药剂因素、内源性物质、活性代谢物、立体异构药物和高变异性药物等方面对生物等效性研究在技术指南及实际应用中需要特别注意的问题进行了具体论述,同时对生物药剂学分类系统等生物等效性研究的相关进展做了初步介绍。 Bioequivalence study plays a key role in drug development including new drug products non- patent generic equivalents, and those after available on market. Some specific problems, such as experimental method, pharmaceutical factors, endogenous substances, active metabolite, isomerizes and high variability, in bioequivalence study and related progress of technic guidance with proctical application were discussed, and biopharmaceutics classification system dealing with bioequivalence was also recommended in this paper.
作者 涂洪谊 温明
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第5期378-383,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 药物评价 临床试验 药动学 生物等效性 drug evaluation clinical trials pharmacokinetics bioequivalence
  • 相关文献

参考文献27

  • 1MARZO A. Open questions on the equivalence: some problems and some solutions[J]. Pharmacol Res, 1999, 40(4) :357-368.
  • 2BENET LZ. Understanding bioequivalence testing[J]. Transplant Proc, 1999, 31(3A Suppl) : 7S-9S.
  • 3ZHREDEV VP, KOLYVANOV GB, LITVIN AA, et al. Harmonization of testing drugs for bioequivalence: problems and possible solutions[J]. Eksp Klin Farmakol, 2003, 66(2) :60-64.
  • 4BORGHEINI G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs[J]. Clin Ther, 2003, 25(6) : 1578-1592.
  • 5GATCHEV E, THYROFF-FRIESINGER U, BAKRACHEVA N, et al. Analysis of pooled plasma samples as a predictor for proving bioequivalence of drugs with a long elimination half-life. The example of phenprocoumon[J]. Arzneimittelforschung, 2004, 54(10) : 685-689.
  • 6NIAZI SK, ALAM SM, AHMAD SI. Partial-area method in bioequivalence assessment: naproxen[J]. Biopharm Drug Dispos, 1997, 18(2): 103-116.
  • 7U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, March 2003. http://www.fda.gov/eder/guidance/index.htm.
  • 8CHEN ML, PATNAIK R, HAUCK WW, et al. An individual bioequivalence criterion: regulatory considerations[J]. Stat Med, 2000, 19(20): 2821-2842.
  • 9SCHALL R, LUUS HG. On population and individual bioequivalence[J]. Stat Med, 1993, 12(12) : 1109-1124.
  • 10吴畏,何凤慈.生物等效性评价中的若干问题[J].中国药业,2004,13(10):23-25. 被引量:2

二级参考文献18

  • 1晁敬东,胡继承,李屯,程强.MIC关联的参数在头孢羟氨苄颗粒剂生物等效性试验中的应用[J].中国临床药理学杂志,1996,12(3):153-159. 被引量:1
  • 2Ministry of Health and Welfare. Guideline for bioequivalence studies of generic products. 1997,Dec., 487.
  • 3Steinijans VW,Trautmann H,Johnson E, et al. Theophylline steadystate pharmacokin ,etics:recent concepts and their application in chronotherapy of reactive airway disease. Chronobiology International, 1987;4:331~347.
  • 4Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rate in investigations of bioequivalence. Iht J Clin Pharmacol,Therapy Toxicology, 1991;29:394~399.
  • 5Blume HH and Midha KK. Bio-International'92,conference on bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci, 1993;82:1186~ 1189.
  • 6Srinivas NR,Barr WH, Shyu WC, et al. Bioequivalence of two tablet formulations of nadolol using single and multiple dose data:Assessment using stereospecific assays. J Pharm Sci,1996;85:299~303.
  • 7Shah V, Yacobi A, Bart W, et al. Evaluation of oially administered highly variable drugs and drug formulations. Pharm Res, 1996; 13:1590~ 1594.
  • 8World Health Organization. Multi-source pharmaceutical products:WHO guideline on registration requirements to establish interchangeability,WHO technical report series,TRS863,1996.
  • 9Food and Drug Administration. Food effect bioavailability and bioequivalence studies(draft guideline),Oct, 1997.
  • 10Food and Drug Administration. Guidance for industry immediate release solid oral dosage forms scale-up and postapproval changes:chemistry, manufacturing, and controls, in vitro dissolution testing,and in vivo bioequivalence documentation,Nov.,1995.

共引文献7

同被引文献62

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部